NCT05212532View on ClinicalTrials.gov

A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms

PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

February 28, 2022

Study Completion Date

March 30, 2022

Conditions
COVID-19 PneumoniaCOVID-19 Respiratory InfectionCOVID-19 Acute Respiratory Distress Syndrome
Interventions
DRUG

EOM613

peptide nucleic acid (PNA)

Trial Locations (4)

21040-900

RECRUITING

Oswaldo Cruz, Manguinhos

14784-400

RECRUITING

Hospital de Amor, Barretos

Unknown

RECRUITING

Hospital Municipal de Barueri, Barueri

RECRUITING

Casa De Saúde, Boqueirão

Sponsors
All Listed Sponsors
lead

EOM Pharmaceuticals

INDUSTRY

NCT05212532 - A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms | Biotech Hunter | Biotech Hunter